AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly deal
More details have emerged about how the industry’s largest psychedelic biotech buyout came to fruition. In an SEC filing on Thursday morning, AtaiBeckley disclosed some of the play-by-play from its
July 30, 2026 11:10 AM EDT Deals AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly deal Kyle LaHucik Biotech Correspondent More details have emerged about how the industry’s largest psychedelic biotech buyout came to fruition. In an SEC filing on Thursday … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that